Cargando…

Change of Body Weight and Macrophage Inhibitory Cytokine-1 during Chemotherapy in Advanced Gastric Cancer: What Is Their Clinical Significance?

BACKGROUND: Weight loss in advanced gastric cancer (GC) has been widely acknowledged to be a predictor for poor survival. However, very few studies have investigated the weight loss that occurs during chemotherapy. Therefore, we focused on weight loss during chemotherapy in patients with advanced GC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Zhihao, Yang, Li, Yu, Jingwei, Lu, Ming, Zhang, Xiaotian, Li, Jian, zhou, Jun, Wang, Xicheng, Gong, Jifang, Gao, Jing, Li, Jie, Li, Yan, Shen, Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3938426/ https://www.ncbi.nlm.nih.gov/pubmed/24586342 http://dx.doi.org/10.1371/journal.pone.0088553

Ejemplares similares

Correction: Change of Body Weight and Macrophage Inhibitory Cytokine-1 during Chemotherapy in Advanced Gastric Cancer: What Is Their Clinical Significance?
Publicado: (2014)

Pretreatment lymphopenia is an easily detectable predictive and prognostic marker in patients with metastatic esophagus squamous cell carcinoma receiving first‐line chemotherapy
por: Kou, Furong, et al.
Publicado: (2016)

Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial
por: Lu, Ming, et al.
Publicado: (2016)

Pyrotinib alone or in combination with docetaxel in refractory HER2‐positive gastric cancer: A dose‐escalation phase I study
por: Liu, Dan, et al.
Publicado: (2023)

Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial
por: Cao, Yanshuo, et al.
Publicado: (2022)

Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study
por: Li, Jie, et al.
Publicado: (2016)

Clinical significance of phenotyping and karyotyping of circulating tumor cells in patients with advanced gastric cancer
por: Li, Yilin, et al.
Publicado: (2014)

Clinicopathological Characteristics and Response to Chemotherapy in Treatment-Naive Epstein–Barr Virus Associated Gastric Cancer: A Retrospective Study
por: Xie, Tong, et al.
Publicado: (2021)

Hyperprogression after immunotherapy in patients with malignant tumors of digestive system
por: Ji, Zhi, et al.
Publicado: (2019)

Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer
por: Li, Yilin, et al.
Publicado: (2016)

Hepatoid adenocarcinoma of the stomach: a unique subgroup with distinct clinicopathological and molecular features
por: Wang, Yakun, et al.
Publicado: (2019)

Diagnostic value of macrophage inhibitory cytokine 1 as a novel prognostic biomarkers for early gastric cancer screening
por: Ge, Xin, et al.
Publicado: (2020)

Expression of macrophage inhibitory cytokine-1 in early gastric cancer cases treated using endoscopic mucosal resection and the correlation with prognosis
por: Zhang, Na, et al.
Publicado: (2017)

Nimotuzumab Plus Paclitaxel and Cisplatin as a 1(st)-Line Treatment for Esophageal Cancer: Long Term Follow-up of a Phase II Study
por: Zhang, Xiaodong, et al.
Publicado: (2019)

Characteristics and Prognosis of Acquired Resistance to Immune Checkpoint Inhibitors in Gastrointestinal Cancer
por: Zhuo, Na, et al.
Publicado: (2022)

Serological Markers Associated With Response to Immune Checkpoint Blockade in Metastatic Gastrointestinal Tract Cancer
por: Lu, Zhihao, et al.
Publicado: (2019)

Hyperglycemic Myocardial Damage Is Mediated by Proinflammatory Cytokine: Macrophage Migration Inhibitory Factor
por: Yu, Xi-Yong, et al.
Publicado: (2011)

Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers
por: Wang, Yanni, et al.
Publicado: (2022)

Real‐world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer
por: Xu, Ting, et al.
Publicado: (2023)

A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer
por: Jiao, Xi, et al.
Publicado: (2021)

Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
por: Yang, Liu, et al.
Publicado: (2022)

CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer
por: Qi, Changsong, et al.
Publicado: (2023)

Prediction of immune checkpoint inhibition with immune oncology-related gene expression in gastrointestinal cancer using a machine learning classifier
por: Lu, Zhihao, et al.
Publicado: (2020)

Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor
por: Chen, Yang, et al.
Publicado: (2021)

Serum macrophage inhibitory cytokine‐1 as a clinical marker for non–small cell lung cancer
por: Xu, Chunhua, et al.
Publicado: (2021)

Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer
por: Wang, Yujiao, et al.
Publicado: (2022)

Use of Radiomics to Predict Response to Immunotherapy of Malignant Tumors of the Digestive System
por: Ji, Zhi, et al.
Publicado: (2020)

Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial
por: Lu, Zhihao, et al.
Publicado: (2021)

Macrophage Migration Inhibitory Factor: A Multifunctional Cytokine in Rheumatic Diseases
por: Kasama, Tsuyoshi, et al.
Publicado: (2010)

The Prognostic and Clinicopathological Significance of Tumor-Associated Macrophages in Patients with Gastric Cancer: A Meta-Analysis
por: Yin, Songcheng, et al.
Publicado: (2017)

Positive Status of Epstein-Barr Virus as a Biomarker for Gastric Cancer Immunotherapy: A Prospective Observational Study
por: Xie, Tong, et al.
Publicado: (2020)

Interactions between Autophagy and Inhibitory Cytokines
por: Wu, Tian-tian, et al.
Publicado: (2016)

Macrophage Inhibitory Cytokine 1 (MIC-1/GDF15) Decreases Food Intake, Body Weight and Improves Glucose Tolerance in Mice on Normal & Obesogenic Diets
por: Macia, Laurence, et al.
Publicado: (2012)

PTCH1 mutation promotes antitumor immunity and the response to immune checkpoint inhibitors in colorectal cancer patients
por: Wang, Yanni, et al.
Publicado: (2021)

Clinicopathological features and lymph node and distant metastasis patterns in patients with gastroenteropancreatic mixed neuroendocrine‐non‐neuroendocrine neoplasm
por: Zhang, Panpan, et al.
Publicado: (2021)

Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study
por: Wang, Xicheng, et al.
Publicado: (2017)

Aneuploidy of chromosome 8 in circulating tumor cells correlates with prognosis in patients with advanced gastric cancer
por: Li, Yilin, et al.
Publicado: (2016)

Macrophage migration inhibitory factor family proteins are multitasking cytokines in tissue injury
por: Song, Shanshan, et al.
Publicado: (2022)

Modulatory role of macrophage migration inhibitory factor on cytokines and clinical features of sarcoidosis
por: Elahi, Morvarid, et al.
Publicado: (2022)

Promotion of Sema4D expression by tumor-associated macrophages: Significance in gastric carcinoma
por: Li, Han, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4es5g78gk2qpplblv7uqjvv97l